EarningsYahoo· —
Eli Lilly Stocks Rise 2.32% While Revenue Guidance Faces a Quality-of-Growth TestThe latest quarter includes benefits that should be separated from underlying demand.
Eli Lilly and Company · NYSE
The latest quarter includes benefits that should be separated from underlying demand.
The Danish drugmaker has had a dismal year, but its third-quarter earnings on Wednesday finally gave the market a reason to feel hopeful.
For questions about this article or underlying research, email help@trefis.com.
The fund bought $175.3 million of stock, lifting all 60 of its positions with no sales.
ETFs bought $105.3 million of Eli Lilly (LLY) stock on Monday.
Eli Lilly and Company is a top AI-driven drug discovery stock, with strong earnings growth, new market potential, and near-term upside. Learn more about LLY stock here.
Eli Lillyâs revenue surged on strong tirzepatide demand, but pricing and patent risks loom. Click here to read an analysis of LLY stock now.
Eli Lilly, Cisco and KLA lead today's featured research reports, with strong demand, AI-driven growth and expanding product opportunities supporting their prospects.
Eli Lilly delivered strong Q3 results, but underlying growth slowed from 49% to 35% and price erosion deepened. Read more on LLY stock here.
Eli Lilly's weight-loss drugs get all the headlines, but CEO David Ricks is betting the company's next act looks nothing like its last one. Here is what it would actually take for shares to reach $1,700 in 2027.
A plain-language read on what may be behind the move: sector peers, related headlines and the macro backdrop. Free with an account.